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Abstract
A more complete understanding of the genetic basis of drug resistance in Mycobacterium 
tuberculosis is critical for prompt diagnosis and optimal treatment, particularly for toxic second-
line drugs like D-cycloserine. Here, we used whole-genome sequences from 498 strains of M. 
tuberculosis to identify novel resistance-conferring genotypes. By combining association and 
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correlated evolution tests with strategies for amplifying signal from rare variants, we found that 
loss-of-function mutations in ald (Rv2780), encoding L-alanine dehydrogenase, were associated 
with unexplained drug resistance. Convergent evolution of this loss-of-function was observed 
exclusively among multidrug-resistant strains. Drug susceptibility testing established that ald loss-
of-function conferred resistance to D-cycloserine, and susceptibility to the drug was partially 
restored by complementation of ald. Clinical strains with mutations in ald and alr exhibited 
increased resistance to D-cycloserine when cultured in vitro. Incorporation of D-cycloserine 
resistance in novel molecular diagnostics could allow for targeted utilization of this toxic drug 
among patients with susceptible infections.
Introduction
Molecular diagnostic testing has transformed pathogen identification and subsequent drug 
susceptibility testing (DST) in the field of clinical microbiology
1
. In particular, the recent 
adaptation of rapid genotypic diagnostics for Mycobacterium tuberculosis
2,3 has 
revolutionized the detection of M. tuberculosis and determination of drug resistance by 
assaying for the presence of specific resistance-conferring mutations. To minimize morbidity 
and mortality of drug-resistant M. tuberculosis, it is critical to treat patients with 
antitubercular drugs to which their infecting strains are susceptible
4,5, and also to prescribe 
the minimally toxic regimen that is capable of curing the disease
6
. However, current 
genotypic diagnostics for M. tuberculosis are limited in that they identify only a subset of 
previously known resistance mutations, and the catalog of mutations that confer resistance is 
incomplete. For example, the Hain Genotype MTBDRsl test
3
 (see URLs) can provide 
insight into second-line drug resistance in M. tuberculosis strains, but only interrogates a 
limited number of resistance mutations and fails to diagnose one in three to four cases of 
extensively drug-resistant tuberculosis (XDR TB)
7
. As many second-line drugs included in 
MDR regimens are highly toxic
8–12 incomplete data provided by current molecular tests 
may result in needless exposure to toxic agents, for example in the case of rifampicin mono-
resistance detected up by GeneXpert
2
 that is treated as MDR.
D-cycloserine is one such highly toxic second-line drug that is not evaluated by current 
molecular diagnostics. The World Health Organization (WHO) has classified D-cycloserine 
as a category 4 drug for the treatment of TB, indicating that it is an oral bacteriostatic 
second-line agent. D-cycloserine remains a cornerstone of MDR and XDR-TB treatment 
despite severe psychiatric and central nervous system toxicities
9,10,12. With these associated 
toxicities, it would be ideal to further restrict its use to patients harboring strains that are 
susceptible to D-cycloserine. Phenotypic DST for D-cycloserine has only been validated on 
Löwenstein-Jensen media; however, routine phenotypic DST is performed infrequently and 
is not recommended by the WHO due to technical difficulties with the assay
13–15.
Given these difficulties with phenotypic resistance characterization and toxicities, it would 
be ideal to detect D-cycloserine resistance via rapid molecular diagnostics. However, the 
molecular basis of D-cycloserine resistance among clinical isolates of M. tuberculosis is 
poorly understood. D-cycloserine functions by competitively inhibiting two enzymes in the 
alanine metabolism pathway—alanine racemase (encoded by alr, Rv3423c)
16
, and D-alanine 
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D-alanine ligase (encoded by ddlA, Rv2981c)
17,18—which are essential for peptidoglycan 
synthesis. Overexpression of alr and ddlA have been previously shown to confer resistance 
to D-cycloserine in Mycobacterium smegmatis
19,20, and acquisition of a nonsynonymous 
mutation in alr in M. tuberculosis was shown to be correlated with the acquisition of 
phenotypic resistance to D-cycloserine
21,22. In addition, Mycobacterium bovis BCG, a live 
attenuated vaccine strain derived from M. bovis, is intrinsically resistant to cycloserine
23
, a 
phenotype that is only partially explained by a mutation in cycA (an alanine transporter)
24
. 
However to our knowledge no mutations in M. tuberculosis have been experimentally 
validated as conferring resistance to D-cycloserine and there is uncertainty over the critical 
concentration that defines resistance.
Recently, whole-genome sequencing has provided more complete information about the 
genetic content of drug-resistant M. tuberculosis
21,25–28, including investigations that have 
used signatures of convergent evolution and positive selection to search for novel genes 
involved in drug resistance
25,26. Here, we combined two large studies of M. tuberculosis
26,28 
with comparable whole-genome sequencing and phenotypic drug resistance data to identify 
mutations that associate with drug resistance. These two studies, from South Africa and 
China, included a total of 498 strains with varying degrees of drug resistance, including 
large numbers of MDR and XDR strains. By utilizing strategies for amplification of signal 
from rare variants, and by combining an association test with a correlated evolution test, we 
identified the gene L-alanine dehydrogenase, ald (Rv2780), as a candidate novel drug 
resistance-conferring gene. We then demonstrated that loss-of-function of ald confers 
resistance to D-cycloserine in vitro, and that clinical strains with ald loss-of-function 
mutations were resistant to this drug.
Results
Identification of candidate resistance-conferring variants
We first compiled a dataset of 498 strains of M. tuberculosis from South Africa and China, 
including whole-genome sequencing and phenotypic drug resistance data
26,28. We next 
sought to assess how much unexplained drug resistance was present among these strains by 
comparing genomic variants detected in each strain to a list of resistance-associated variants 
for eight drugs drawn from current diagnostics and literature (Supplementary Note, and 
Supplementary Tables 1–2). The amount of unexplained drug resistance varied by drug, with 
anywhere between 8 and 21 strains without known resistance conferring mutations per drug 
(Table 1). Given the limited numbers of strains that were phenotypically resistant but lacked 
known genotypic resistance mechanisms to individual drugs, we reasoned that novel 
mechanisms of resistance might be rare and difficult to identify statistically based on 
individual variants. We therefore collapsed the genotypic data using two approaches: first by 
frequency in the population, and second based on functional impact (Methods). Specifically, 
in the second approach, we collapsed different loss-of-function mutations (defined as a 
nonsense mutation, frameshift, or large in-frame insertion or deletion (indel)) within the 
same gene, as loss-of-function of select genes are known to confer resistance to select drugs 
in M. tuberculosis
29–33. Synonymous single-nucleotide polymorphisms (SNPs) were 
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excluded in both approaches. Using these criteria, a combined set of 11,704 genotypic 
features was generated for downstream analysis.
To identify novel resistance conferring mutations in this dataset, we hypothesized that 
resistance-conferring genotypes should follow two patterns: 1) there should be a positive 
correlation between presence of a resistance-conferring mutation and presence of phenotypic 
resistance, and 2) a resistance-conferring mutation and phenotypic resistance should evolve 
convergently and in concert, i.e., they should evolve repeatedly and at the same times in 
evolutionary history. We therefore conducted two tests: a Fisher’s exact test to measure the 
direct association between genotype and phenotype, and a test for correlated evolution
34
 of 
genotype and phenotype, and then combined the p-values from both tests into an F-score 
(Methods).
Analysis of this combined set of genotypic features with the Fisher’s exact and correlated 
evolution tests for each drug revealed that, in almost all cases, mutations already known to 
confer drug resistance were the most significant genotypic features resulting in the highest 
combined F-scores (Figure 1, Supplementary Table 3). However, for most drugs, genotypic 
features known to confer resistance to drugs other than the one being analyzed in the 
association tests were also often highly significant across both tests yielding high F-scores. 
For example, mutations in katG, pncA, rpoB, embB, and rpsL were significantly associated 
with isoniazid resistance despite the fact that katG is the only gene on this list which confers 
resistance to isoniazid. This is due to the fact that drugs to treat M. tuberculosis are 
prescribed only in combination and, therefore, resistances frequently co-occur.
Remaining high scoring features included genes encoding PE-PGRS proteins, polyketide 
synthases, secretion-associated proteins, and hypothetical proteins (Supplementary Table 3). 
However, when further examined, none of these other high scoring features could account 
for a large fraction of phenotypic resistance in strains without known genotypic resistance 
mechanisms. Rather, these features most often appeared in strains where phenotypic 
resistance could already be explained by known resistance-conferring mutations.
Loss-of-function correlated with unexplained resistance
Given that the list of highest scoring features contained a significant number of genes 
already associated with resistance, and that the remaining high scoring features co-occurred 
with known resistance-conferring mutations, we hypothesized that the strong statistical 
signal contributed by mutations in these genes could make the identification of novel, low 
frequency resistance mechanisms difficult. To amplify signal from strains with potential for 
novel resistance genotypes, we repeated the association analysis after removing strains with 
known resistance-conferring mutations (Supplementary Figure 1, Supplementary Table 4).
From this analysis, we identified 21 genes with loss-of-function mechanisms that associated 
with phenotypic resistance to at least one of nine drugs (excluding PE/PPE genes and 
transposable elements; Supplementary Tables 4, 5). Eight of these drug resistance-associated 
genes were represented in a library of M. tuberculosis single gene knockout mutants with 
gene interruption conferred by a kanamycin resistance cassette
35
. We screened all available 
knockout mutants representing these eight genes against a panel of five antitubercular drugs 
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(plus the positive control kanamycin). We observed no resistance above the critical 
concentration to any of the tested drugs other than kanamycin, indicating that loss-of-
function of each of these genes alone is insufficient to confer resistance to this particular 
panel of drugs (Supplementary Table 6).
One gene, ald (Rv2780), was notable in that it had an especially high number of unique loss-
of-function mutations that appeared to evolve in a pattern consistent with convergent 
evolution. We identified 11 different ald loss-of-function mutations in 25 South African 
strains across four different spoligotypes, including one nonsense mutation and ten distinct 
indels (Figure 2A, Supplementary Table 7). When examined within a phylogenetic context, 
ald loss-of-function mutations appeared to evolve exclusively and repeatedly in MDR and 
XDR genetic backgrounds, suggesting a selection for loss-of-function of this gene among 
patients receiving second-line drug regimens (Figure 2B). Four other genes had loss-of-
function mutations occur exclusively within an MDR and XDR genetic background 
(Rv1250, Rv2042c, Rv3197A: whiB7, and Rv3823c: mmpl8), although in all cases at a 
much lower frequency than ald (Supplementary Table 5). The role of loss-of-function 
mutations in these genes is unclear, as Rv1250 expression is induced by drug exposure
36
, 
mmpl8 expression has been positively correlated with virulence
37
, and overexpression of 
whiB7 has been shown to confer cross-resistance to aminoglycosides
38,39 while null mutants 
have been shown to be hypersusceptible to multiple antibiotics including macrolides
40,41 
(Supplementary Note).
ald loss-of-function conferred resistance to D-cycloserine
The ald gene encodes L-alanine dehydrogenase, a component of the alanine metabolism 
pathway, which includes the targets of the second-line drug D-cycloserine (Figure 3)
42
. D-
cycloserine resistance was not prospectively phenotypically assayed in the 498 strains 
analyzed here; however, D-cycloserine and terizidone, a dimeric form of D-cycloserine, are 
routinely prescribed as part of the South African drug-resistant M. tuberculosis treatment 
guidelines (see URLs). Therefore, MDR and XDR M. tuberculosis in this region could have 
developed D-cycloserine resistance due to selective drug pressure.
To investigate whether ald loss-of-function conferred resistance to D-cycloserine, we 
determined the minimum inhibitory concentration (MIC) on Löwenstein-Jensen (LJ) media 
(Methods) for four strains: 1) CDC1551, a fully drug-susceptible reference strain of M. 
tuberculosis (with wild type alleles of ald, alr, ddlA, and cycA), 2) an ald knockout strain 
(Δald), 3) the ald knockout complemented with wild type ald (Δald-comp) from M. 
tuberculosis, and 4) M. bovis BCG Danish 1331 (BCG), a strain known to be naturally 
resistant to D-cycloserine
23,43. Testing was repeated in multiple independent experiments to 
establish reproducibility of the assay; results are shown in Table 2. Wild type M. 
tuberculosis was the most susceptible to D-cycloserine (MIC = 15 μg/mL) while the positive 
control BCG was the most resistant (MIC = 40–60 μg/mL). The ald knockout had increased 
resistance relative to the wild type strain (MIC = 25–30 μg/mL), which overlaps the WHO-
determined critical concentration for resistance on LJ of 30 μg/mL (see URLs). 
Complementation of ald partially restored susceptibility to D-cycloserine (MIC = 20 μg/
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mL). These results demonstrate that in vitro, ald loss-of-function confers a moderate level of 
resistance to D-cycloserine.
These results were also confirmed in a growth advantage assay, in which all strains were 
cultured in a mycobacterial growth indicator tube (MGIT) system with varying 
concentrations of D-cycloserine (0, 7.5 and 15 μg/mL) and the resulting time to positivity in 
the presence of the drug was normalized to the no-drug control (Figure 4, Methods, 
Supplementary Figure 2). The ald knockout had a significant growth advantage relative to 
the wild type strain at 7.5 μg/mL D-cycloserine, (p < 0.0001, ANOVA), and no significant 
growth difference when compared to the resistant control strain, BCG, at the same drug 
concentration (Figure 4A). At a higher concentration of D-cycloserine (15 μg/mL), the ald 
knockout still retained a growth advantage over the wild type strain (Figure 4B; p < 0.0001, 
ANOVA), but grew more slowly relative to BCG (p < 0.0001, ANOVA), supporting the MIC 
data, which showed that ald loss-of-function confers less resistance than the mechanism 
present in BCG. At both drug concentrations, the ald complement partially reverted the 
growth advantage conferred by the ald knockout (Figure 4A, B; p < 0.0001, ANOVA).
Within the M. tuberculosis complex (MTBC), BCG is uniquely considered resistant to D-
cycloserine
44
. This resistance was previously shown to be, at least partly, due to a unique 
SNP in cycA, which encodes an alanine transporter
24,45. However, all of the RD9 lineages of 
MTBC from M. africanum to M. bovis, including BCG, have a frameshift in ald causing 
loss-of-function (Supplementary Figure 3)
46,47. We therefore sought to evaluate the effect of 
the frameshift in both the BCG and more general RD9 genetic background by determining 
the MIC of two additional strains: 1) M. bovis ATCC 19210, a reference strain of M. bovis, 
and 2) M. bovis BCG complemented with M. tuberculosis ald (BCG-ald-comp). M. bovis 
ATCC 19210 had a D-cycloserine MIC of 25 μg/mL (Table 2), which is similar to the level 
of resistance observed in Δald and greater than the level of resistance observed in the M. 
tuberculosis reference strain, CDC1551. The ald-complemented BCG strain had an MIC of 
40 μg/mL, which was not different from the wild type BCG strain (Table 2), although in a 
growth advantage assay at low concentrations of D-cycloserine, BCG had a significant 
growth advantage when compared to the ald-complemented BCG strain, (p < 0.02 and p < 
0.0001; Supplementary Note, Supplementary Figures 4 and 5). Taken together, these results 
suggest that ald loss-of-function may have both a minor role in the resistance of BCG to D-
cycloserine, and provide M. bovis with an elevated resistance to D-cycloserine relative to M. 
tuberculosis.
ald and alr in D-cycloserine resistant clinical isolates
To more specifically ascertain the distribution and diversity of mutations in ald, along with 
mutations in alr, ddlA, and cycA, we characterized all promoter, nonsynonymous, and loss-
of-function mutations in these four genes across all strains in our dataset (Table 3, 
Supplementary Table 8). Mutations were most frequent in ald (25 strains), followed by alr 
(17 strains). Only seven strains were identified to have mutations in either ddlA or cycA; 
none of these mutations corresponded to previously characterized resistance-conferring 
mutations. We observed that many more strains had ald loss-of-function mutations than had 
ald nonsynonymous mutations (24 versus 5, respectively). By contrast, mutations in alr were 
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exclusively nonsynonymous, with the exception of one strain with a SNP in the promoter 
region, supporting the hypothesis that alr is essential
48
.
We next sought to verify our prediction that clinical strains with ald loss-of-function 
mutations would exhibit resistance to D-cycloserine, and to determine how that level of 
resistance compared to strains with mutations in alr. We selected 44 clinical isolates from 
South Africa for testing, including 22 with wild type ald and alr, 13 with mutations in ald 
and wild type alr, 7 with wild type ald and mutations in alr or its promoter, and 2 with 
mutations in both ald and alr (Supplementary Table 9). These strains had diverse drug 
susceptibility phenotypes and varying genetic backgrounds (Supplementary Table 9).
Clinical isolates with ald mutations showed significantly increased resistance to D-
cycloserine relative to strains with wild type alleles of both ald and alr (Figure 5A, 
Supplementary Table 9; p < 0.0002, Mann-Whitney U test). Strains with ald loss-of-function 
mutations had a median MIC of 40 μg/mL, with 8 of those 11 strains exhibiting an MIC 
from 30–40 μg/mL. The two strains with nonsynonymous SNPs in ald had MICs of 30 
μg/mL; both of these nonsynonymous SNPs were predicted to have a deleterious effect on 
protein function by PROVEAN
49
 (Supplementary Table 9). By contrast, strains with wild 
type alleles in both genes had a median MIC of 20 μg/mL, with 91% of strains exhibiting 
MICs <= 20 μg/mL. These data suggest that both deleterious nonsynonymous SNPs and 
loss-of-function mutations in ald can cause resistance to D-cycloserine in clinical isolates of 
M. tuberculosis at or above the current critical concentration (30 μg/mL; URLs).
Clinical isolates with alr mutations also showed increased resistance to D-cycloserine 
relative to strains with wild type alleles of both ald and alr (Figure 5A, Supplementary Table 
9). Of the strains with nonsynonymous mutations in alr, 4 of 6 exhibited high level 
resistance to D-cycloserine, with MICs of >=60 μg/mL, while one, plus the two strains with 
both alr and ald mutations, exhibited MICs of 40 μg/mL. As with ald, all of the 
nonsynonymous SNPs seen in alr were predicted to have a deleterious effect on protein 
function by PROVEAN
49
 (Supplementary Table 9). Additionally, the one strain with an alr 
promoter mutation showed high level resistance (MIC > 60 μg/mL), consistent with previous 
results in M. smegmatis that showed upregulation of alr through a promoter mutation 
conferred resistance to D-cycloserine
19
. These results suggest that both nonsynonymous 
SNPs in alr and SNPs in the alr promoter can confer high-level resistance to D-cycloserine 
in clinical isolates of M. tuberculosis, and that alr and ald mutations are non-additive for 
resistance.
Discussion
To identify novel drug resistance-conferring mechanisms in M. tuberculosis, we analyzed 
whole-genome sequencing data from two large collections of clinical isolates from South 
Africa and China with diverse phenotypic drug resistance profiles. Combining a direct 
association test with a correlated evolution test followed by functional screening of the top 
scoring genes with loss-of-function mutations, we identified a novel drug resistance 
mechanism to D-cycloserine, ald loss-of-function, which we then validated experimentally. 
We further showed that clinical strains with mutations in ald and alr, identified through our 
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computational analyses, were resistant to D-cycloserine. Collectively, this work expands our 
understanding of D-cycloserine resistance in M. tuberculosis and provides new opportunities 
to detect and manage D-cycloserine resistant TB.
The strong linkage disequilibrium and stratification present in bacterial populations has long 
been highlighted as a major hurdle for bacterial genome-wide association studies
50
. 
However, the problem of interdependence is not restricted to genotypes, but extends to drug 
resistance phenotypes as well
26
. For most TB drugs, mutations known to confer resistance to 
a single drug were significantly associated with phenotypic resistance to numerous unrelated 
drugs. This is because TB is treated exclusively with multi-drug regimens, which makes it 
difficult to collect clinical isolates of M. tuberculosis with independent drug resistance 
phenotypes. However, combining a basic association test with a correlated evolution test 
appeared to mitigate this phenotypic interdependence, as it could often correctly match 
known resistance mechanisms with the correct drug; the method did have difficulty when the 
resistance-conferring genotype evolved infrequently (e.g., pyrazinamide; Supplementary 
Note) and had other limitations (Supplementary Note). Ultimately, to robustly overcome 
phenotypic interdependence in association studies of drug resistant M. tuberculosis, further 
methods development is needed to build upon this and other work
25,26.
After we identified loss-of-function mutations in ald as a candidate novel drug resistance 
mechanism, we showed experimentally that ald loss-of-function confers resistance to D-
cycloserine in M. tuberculosis. Complementation of ald back into the ald knockout strain 
partially restored susceptibility to D-cycloserine (partial restoration by complementation has 
been observed before in M. tuberculosis, and could be due to altered expression levels 
through usage of a non-native promoter
51
). We hypothesize that strains lacking functional 
Ald are unable to convert L-alanine to pyruvate, thereby increasing the pool of available L-
alanine (Figure 3). As L-alanine is the precursor to the pathway steps competitively inhibited 
by D-cycloserine, abundant L-alanine in the setting of non-functional Ald may allow for 
continued alanine racemization and D-alanine ligase activity, and therefore continued 
peptidoglycan production despite competitive inhibition by D-cycloserine. However, the 
observation in clinical strains that ald loss-of-function conferred a lower level of resistance 
than nonsynonymous or promoter mutations in alr (Supplementary Table 9), the direct target 
of D-cycloserine, suggests that the resistance conferred by ald could more easily be 
overcome through increased dosage of D-cycloserine.
M. bovis and other members of the MTBC that lack RD9
52
 share a frameshift in ald. We 
sought to determine the effect of this frameshift in M. bovis strains traditionally classified as 
D-cycloserine resistant (BCG) and susceptible (all other strains)
44
. We observed that the M. 
bovis reference strain, ATCC 19210, had elevated levels of D-cycloserine resistance as 
compared to clinical isolates of M. tuberculosis lacking resistance-conferring mutations. Our 
results suggest that M. bovis, and potentially the entire RD9 lineage, which is generally 
considered D-cycloserine susceptible, may actually have elevated resistance levels (Figure 
5B, URLs). However, much of the RD9 lineage (including M. bovis, but excluding BCG) 
also shares an inactivating mutation in the gene encoding pyruvate kinase (pykA), which 
provides pyruvate to Ald
53,54 and could, therefore, potentially confound analysis of D-
cycloserine resistance among these strains. Evolutionary analyses suggest that in animal-
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infecting species of the MTBC there is more ancient functional diversity of these genes than 
in M. tuberculosis sensu stricto (Supplementary Note, Supplementary Figure 3). Future 
experiments to disentangle the roles of ald, pykA and other related genes in drug resistance 
across the other species of the MTBC will be needed.
The identification of so many unique ald loss-of-function mutations among drug-resistant 
clinical strains of M. tuberculosis suggests that, despite conferring only a moderate level of 
resistance, this mechanism provides sufficient resistance to be selected for under current 
drug exposure pressures in South Africa (Supplementary Note). This further suggests that 
ald loss-of-function mutations confer resistance to the D-cycloserine analog, terizidone, 
which is routinely prescribed for treatment of drug-resistant M. tuberculosis in South Africa 
(see URLs), although this hypothesis still needs to be tested. While ald loss-of-function may 
prove advantageous during exposure to D-cycloserine or terizidone, harboring such a 
mutation may prove to be deleterious in other settings. Strains with non-functional Ald may 
be unable to increase pyruvate availability under hypoxic conditions, and further laboratory 
investigation should determine whether ald loss-of-function yields decreased survival in 
hypoxia. However, compared to the M. bovis genetic background where pykA is also non-
functional, clinical M. tuberculosis strains with loss-of-function of ald may have greater 
ability to tolerate hypoxic environments (such as in a granuloma) where reliance on pyruvate 
(rather than aerobic metabolism) is greater.
Given the severe psychiatric and central nervous system toxicities of D-cycloserine
9,10,12, it 
is critical to both incorporate D-cycloserine resistance mechanisms into molecular 
diagnostics and optimize phenotypic resistance assays to prevent the drug from being 
inappropriately prescribed to patients who harbor resistant strains. In order to maximize the 
effectiveness of phenotypic resistance assays, the range of wild type MICs for an organism 
must be determined to define drug resistance and to set appropriate critical 
concentrations
55,56. Recently, the Stop TB Partnership recommended to the WHO that the 
critical concentration of D-cycloserine be lowered from 40 to 30 μg/mL (URLs). Assuming 
that the two isolates exhibiting increased resistance to D-cycloserine, but having wild type 
alleles in both ald and alr, harbor an unknown resistance mechanism, our results suggest a 
tentative epidemiological cutoff (ECOFF)
57
 of 20 μg/mL (Figure 5B). Although 
phenotyping of a larger number of strains is required, our results support a lowering of the 
critical concentration below 30 μg/mL. Selection of a critical concentration would also need 
to consider whether it should be applied to M. tuberculosis sensu stricto or the entire MTBC 
including M. bovis.
D-cycloserine resistance is an ideal target for molecular diagnostics, given technical 
difficulties with reproducibility and reliability of the phenotypic resistance assay
13–15. 
However, current SNP-based diagnostics are not amenable to capturing loss-of-function 
mutations, as the mutations can occur anywhere within the gene and thus are difficult to 
capture with a small number of targeted SNPs. Other whole-gene-based diagnostic strategies 
will instead need to be employed, some of which have already been developed for detection 
of drug-resistant TB, such as high-resolution melt (HRM) analysis
58
 and rapid whole-
genome sequencing of clinical isolates
21
. Incorporation of resistance mechanisms to D-
cycloserine and other highly toxic drugs into novel molecular diagnostics could prevent 
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We used two sets of strains in this study: one set of 337 strains from South Africa
28
 (NCBI 
Bioproject ID numbers: PRJNA183624, PRJNA235615) and one set of 161 strains from 
China
26
 (NCBI Sequence Read Archive (SRA) accession number: SRA065095). For both 
sets, reads were mapped onto a reference assembly of H37Rv (GenBank accession number: 
CP003248.2) using BWA version 0.5.9
60
. In cases where read coverage of the reference was 
greater than 200x, reads were down-sampled using Picard (see URLs) prior to mapping. 
Variants were identified using Pilon version 1.5 as described
61
. All sites with unambiguous 
SNPs were used to generate a phylogenetic tree using FastTree version 2.1.3
62
. To assess the 
amount of unexplained phenotypic resistance in our dataset, we identified genomic 
polymorphisms known to confer drug resistance in each strain using variants from current 
diagnostics supplemented with a literature review (Supplementary Note).
In order to identify novel variants conferring drug resistance, we hypothesized that the 
presence of causal genotypes in bacteria should be both positively correlated with 
phenotypes and not evolutionarily independent of them. We therefore conducted two tests, 
the first of which was a Fisher’s exact test to measure the association between genotype and 
phenotype. The second test was a test for correlated evolution
34
 implemented in the software 
package BayesTraits (see URLs). Briefly, the correlated evolution test calculates the 
likelihood of two traits evolving dependently and independently and then compares the two 
models with a likelihood ratio test. If the dependent model is significantly more likely than 
the independent model, the hypothesis of evolutionary independence is rejected. All test 
results were corrected for multiple comparisons using the Benjamini-Hochberg method
59
 for 
plotting purposes. Once both the Fisher’s exact test and the correlated evolution test were 
calculated, their uncorrected p-values were combined into an F-score by taking the harmonic 
mean of the negative log p-values. Uncorrected values were used in the F-score calculation 
to provide maximal discrimination between variants with poor p-values.
In order to compare phenotypic drug resistances to genotypic features, two matrices of these 
features were constructed from the variant calls of all strains. In the first matrix, rare variants 
(those at ≤ 2% frequency) were collapsed by gene or intergenic region, while common 
variants (those at > 2% frequency) remained uncollapsed and were considered 
independently. In the second matrix, we assessed whether each gene had a loss-of-function 
mutation (defined as a nonsense mutation, frameshift, or large (>30 bp) in-frame insertion or 
deletion (indel)), regardless of the frequency of the mutation. We then combined the two 
matrices into a single matrix for association analyses. All analyses were conducted twice: 
once with all samples, and once after removing strains with known resistance-conferring 
mutations, in order to amplify signal from strains with potential for novel resistance 
genotypes (Results).
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DST screen of transposon mutants
Single gene knockout transposon mutants were sourced from the Johns Hopkins TARGET 
mutant collection
35
. First and second-line DST was performed by the agar proportion 
method on 7H11 media, using the following WHO-recommended critical concentrations (in 
μg/mL): isoniazid 0.2, isoniazid 1.0, rifampicin 1.0, ethambutol 7.5, streptomycin 2.0, 
ofloxacin 2.0 and kanamycin 6.0.
ald complementation into CDC1551 and BCG Danish 1331
An ald knockout mutant (Δald) of M. tuberculosis (JHU2780-209) was obtained from the 
Johns Hopkins TARGET mutant collection
35
. This single gene knockout mutant was created 
in a background of wild type M. tuberculosis strain CDC1551 by Himar1 transposon 
mutagenesis with ald interrupted at nucleotide 209, which contains a kanamycin-resistance 
cassette. To complement Δald, a 1.116kb fragment spanning the ald gene was PCR amplified 
from M. tuberculosis H37Rv genomic DNA using primers listed in Supplementary Table 10. 
The fragment was directionally cloned into pMCZ-MOP, an L5 integrating zeocin-marked 
mycobacterial vector to create pMCZ-MOP-ald, which allowed for the expression of ald off 
the MOP (mycobacterial optimized promoter)
63
. The pMCZ-MOP-ald was then transformed 
into Δald to create the Δald complemented strain, resulting in constitutive expression of ald. 
Transformants were selected using the appropriate antibiotic markers and confirmed by 
amplicon sequencing of a 1.319kb fragment of the integrated plasmid spanning the inserted 
ald gene. pMCZ-MOP-ald was also transformed into BCG Danish 1331 (Statens Serum 
Institut) to create the BCG-ald-complement.
M. bovis amplicon sequencing
Amplicon sequencing of ald and pncA
64
 in M. bovis ATCC 19210 confirmed the presence 
of the ald mutation (a266del), and a mutation in pncA (g169c) that is common to all M. 
bovis and BCG strains.
D-Cycloserine MIC determination
Select mycobacterial strains were subjected to D-cycloserine MIC determination on 
Löwenstein–Jensen (LJ) medium. LJ slants were prepared freshly as had been previously 
described per WHO protocols, with supplementation of D-cycloserine prior to inspissation 
to achieve final drug concentrations of 0μg/mL, 10μg/mL, 15μg/mL, 20μg/mL, 25μg/mL, 
30μg/mL, 40μg/mL, 60μg/mL, and 120μg/mL. 103 CFU of a mid to late-log liquid culture of 
M. tuberculosis was inoculated onto D-cycloserine slants at each drug concentration in 
duplicate. Slants were incubated at 37°C for four weeks, after which CFU were counted. The 
MIC to D-cycloserine for each strain was determined to be the lowest drug concentration 
that resulted in 90% reduction in CFU when compared to the no drug control. Differences in 
MIC distributions were calculated using the Mann-Whitney U test; in cases where MICs 
were replicates, the average interval across replicates was used for the calculation.
D-cycloserine growth inhibition assay
All mycobacterial strains were grown under standard conditions, in Middlebrook 7H9 broth 
(Difco) supplemented with 0.5% glycerol, 10% oleic acid-albumin-dextrose-catalase 
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(OADC), and 0.05% Tween 80 with constant shaking at 37°C. On the day of the 
experimental set up, D-cycloserine powder (C6880, Sigma-Aldrich) that had been stored at 
−20°C was freshly dissolved in a 0.1M sodium phosphate buffer (pH 8.0) and sterilized with 
a 0.22μm filter. BD BACTEC™ MGIT™ tubes were prepared with BD BACTEC™ MGIT™ 
growth supplement, and 6.5mL tween-free 7H9 media supplemented with or without D-
cycloserine to achieve a final drug concentration of 0 μg/mL, 7.5 μg/mL, 15 μg/mL and 30 
μg/mL of D-cycloserine. 103 CFU of a mid to late-log liquid culture of M. tuberculosis that 
had been prepared from a single colony isolate of each strain was inoculated into three 
MGIT tubes for each drug concentration to achieve three technical replicates. Dilutions of 
the initial inoculum were plated for CFU in parallel to quantify the starting inoculum. The 
bar code of each MGIT tube was scanned into the BD BACTEC™ MGIT™ 960 
Mycobacterial Detection System, and the MGIT tubes were placed in the instrument as 
directed. Samples remained in the MGIT instrument until they were flagged positive for 
growth, and the time to positivity (ttp) was recorded. Tubes that were not flagged positive by 
42 days were considered to have no growth, and were assigned a ttp value of > 42 days. Data 
were reported for each strain and each drug concentration as a mean ttp for the three 
technical replicates ± the standard error of the mean (SEM). To determine relative growth 
inhibition of each drug concentration for each strain, the ttp of each D-cycloserine-
containing MGIT was normalized to the mean ttp of no drug control for that strain. The 
mean ttp of the no drug control was considered to have a growth inhibition value of 1. 
Growth inhibition was calculated for each MGIT tube and reported as a mean growth 
inhibition for the three technical replicates ± the SEM. Adjusted p-values were calculated 
using a two-way ANOVA with Tukey’s multiple comparisons test in Prism GraphPad 
version 6.0 (GraphPad, San Diego, CA). We also confirmed that the transposon mutagenesis 
did not confer a growth advantage in the presence of D-cycloserine (Supplementary Note, 
Supplementary Tables 11 and 12).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance of associations between genotypic variants and drug resistance phenotypes. 
Each circle represents a genotypic feature that is plotted at the intersection of the negative 
log p-values from Fisher’s exact and correlated evolution tests for each drug. P-values were 
corrected for multiple comparisons using the Benjamini-Hochberg method
59
. Genotypic 
variants known to confer resistance are colored according to the drug to which they confer 
resistance, and genotypes with no known effect on drug resistance are grey. Genotypes 
scoring well in both tests appear in the upper right quadrants.
Desjardins et al. Page 16














Convergent evolution of loss-of-function mutations in ald in MDR and XDR M. 
tuberculosis. A) Positions of insertions, deletions, and nonsense mutations in ald. Insertions 
are marked as blue triangles while deletions and nonsense mutations are marked as red 
triangles. Size of the indel or details of nonsense mutation are shown above or below each 
triangle. The location of the frameshift in BCG is also included. B) Phylogeny of lineage 4 
strains. Inner tick marks denote MDR (gray) and XDR (black) M. tuberculosis. Outer tick 
marks denote insertions (blue) and deletions or nonsense mutations (red).
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Alanine metabolism pathway in M. tuberculosis. L-alanine-dehydrogenase catalyzes the 
NAD-dependent interconversion between L-alanine and pyruvate. Under aerobic conditions 
this reaction allows for the utilization of L-alanine as a nitrogen source, whereas under 
hypoxic conditions this reaction allows for NADH recycling to NAD+. Separately, the initial 
step of peptidoglycan synthesis involves conversion of L-alanine to D-alanine by alanine 
racemase. Two D-alanine molecules are joined by D-ala-D-ala ligase to produce the 
dipeptide D-alanine-D-alanine, which is subsequently incorporated into the pentapeptide 
chain of the peptidoglycan cell wall. Both alanine racemase and D-ala-D-ala ligase are 
competitively inhibited by D-cycloserine, an analog of D-alanine.
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A single gene knockout of ald confers a growth advantage relative to wild type M. 
tuberculosis when cultured in the presence of D-cycloserine. Four laboratory strains—wild 
type M. tuberculosis (WT), ald knockout (Δald ), ald complemented back into Δald (ald-
comp) and BCG—were cultured in triplicate in 0, 7.5 and 15 μg/mL of D-cycloserine. The 
resulting time to positivity (ttp) in MGIT was recorded as days since inoculation, and the 
resulting ttp was normalized to the no drug control for each strain to calculate the growth 
inhibition index for each drug concentration. The mean growth inhibition index is plotted 
with error bars to represent the SEM. P-values were calculated using a two-way ANOVA.
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Clinical strains with mutations in L-alanine dehydrogenase (ald) and alanine racemace (alr) 
exhibit increased resistance to D-cycloserine. A set of 44 clinical strains of M. tuberculosis 
with differing genotypes with respect to ald and alr were selected, representing wild type 
alleles (WT), loss-of-function mutations (LOF), nonsynonymous mutations (NSY) and 
promoter mutations (PRO). The minimum inhibitory concentration (MIC) to D-cycloserine 
was determined for each strain on Löwenstein–Jensen media. For wild type strains and 
strains with ald loss-of-function mutations, the median is shown as an open circle and 
quartiles are shown as connected bars. When compared to WT isolates, strains with ald loss-
of-function had significantly increased resistance to D-cycloserine (p < 0.0002, Mann-
Whitney U test).
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Table 1
Unexplained drug resistance in 498 strains of M. tuberculosis from South Africa and China. The total number 
of strains assayed for phenotypic resistance to each drug is shown, along with the number of phenotypically 
resistant (R) and phenotypically susceptible (S) strains. The number of strains with phenotypic drug resistance 
but without a match to known resistance-associated mutations is also given.
# of phenotyped strains
# strains w/unexplained
RDrug Total R S
Rifampicin 498 337 161 8
Isoniazid 498 350 148 21
Pyrazinamide 142 72 70 12
Ethambutol 394 164 230 15
Streptomycin 498 256 242 21
Ofloxacin 494 162 332 15
Kanamycin 491 104 387 20
Capreomycin 300 66 234 15
Ethionamide 288 102 186 16
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Table 2
Loss-of-function of L-alanine dehydrogenase (ald) confers increased resistance to D-cycloserine in vitro. The 
minimum inhibitory concentration (MIC) to D-cycloserine was determined for each strain on Löwenstein–
Jensen media. Testing was done in three independent experiments (assays #1–#3) to establish reproducibility. 
Dashes indicate those strains were not tested during that experiment.
Strain D-cycloserine MIC (μg/mL)
Assay #1 Assay #2 Assay #3
wild type M. tuberculosis 15 15 -
Δald 25 30 25
ald-comp 20 20 20
BCG 40 40 60
BCG-ald-comp 40 - 40
M. bovis - 25 25
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Table 3
Counts of clinical isolates with mutations in ald, alr, ddlA, and cycA. Mutation types include wild type (no 
mutations; WT) loss-of-function (LOF), nonsynonymous (NSY), and promoter SNPs (PRO); synonymous 
SNPs are excluded. Specific strains and mutations are shown in Supplementary Table 8.
# of Clinical Isolates ald alr ddlA cycA
449 WT WT WT WT
20 LOF WT WT WT
5 NSY WT WT WT
4 LOF NSY WT WT
12 WT NSY WT WT
1 WT PRO WT WT
1 WT WT NSY WT
1 WT NSY WT NSY
5 WT WT WT NSY
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